Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

Fig. 2

Prognostic impact of vimentin- and Ki67-expressing CTC. a-b Prognostic comparison of patients with vimentin-expressing CTC at baseline compared to those with no vimentin-expressing CTC, as assessed by bar charts comparing baseline PSA (a), and Kaplan-Meier plots of overall survival (b). c-d Prognostic comparison of patients with Ki67-expressing CTC at baseline compared to those with no Ki67- expressing CTC, as assessed by bar charts comparing baseline PSA (c), and Kaplan-Meier plots of overall survival (d). Mann-Whitney tests performed for (a) and (c), log-rank tests for (b) and (d); Bar charts show mean +/- standard deviation, p=<0.05

Back to article page